-
Professor Xue Junli, | Brilliant: Focus on immunity, talk about "intestine" things, the opportunities and challenges of coloral cancer immunotherapy
Time of Update: 2022-10-01
Professor Deng Ting, |: standardize "adjuvant", constantly seek innovation, and discuss adjuvant treatment decisions for colorectal cancer PP-FR-CN-0986Past Review 1.
Professor Deng Ting, |: standardize "adjuvant", constantly seek innovation, and discuss adjuvant treatment decisions for colorectal cancer PP-FR-CN-0986Past Review 1.
-
Medical Voice Medical Road | the post-epidemic era colorectal cancer patients to seek medical treatment, oral targeted drugs to escort the post-line treatment
Time of Update: 2022-10-01
*For medical professionals onlyThe "epidemic" road forward, overcome the difficulties of the times, and fruquintinib guarantees the home treatment of colorectal cancer patients in the post-epidemic eraSince the outbreak of the new coronavirus pneumonia (COVID-19) epidemic (hereinafter referred to as the new crown epidemic) in December 2019, it has brought unprecedented challenges to mankind, and although the epidemic has now stabilized, the situation is still grim.
-
BiomaterialsSouth China University of Technology's team Youyong Yuan has developed a reactive oxygen species wake-up self-amplifying degradable polymer for enhancing cancer immunotherapy
Time of Update: 2022-10-01
Endogenous ROS induces TA group cracking to interpret the release of CA, which in turn triggers the degradation process of self-amplifying polymers, and after CA release, more ROS generation is promoted by mitochondrial dysfunction, resulting in large polymer degradation.
-
Micro Classroom No. 12 Prof. Fei Li: Highlights and updates of the 2nd edition of the International Staging System for Total Survival of Multiple Myeloma (R2-ISS).
Time of Update: 2022-10-01
In the subgroup of cytogenetically high-risk patients with revision of 1q+, the MRD negative rate in the D-VRd group after consolidation therapy, after 12 months of maintenance therapy, and 24 months after maintenance therapy was significantly higher than that in the VRd treatment group.
-
Nature Sub-Journal: Shanghai Jiaotong University publishes Chinese pan-genomic analysis of gastric cancer
Time of Update: 2022-10-01
Recently, Zhu Zhenggang, Yu Yingyan, Chen Hongzhuan, Wei Chaochun of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine published a research paper titled "Pangenomic analysis of Chinese gastric cancer" in Nature Communications.
-
In the era of targeted therapy, how to determine the clinical drug dose? ——Take BTKi and PI3Ki as examples
Time of Update: 2022-09-30
Figure 1 Phase I trial of CLL targeted therapy[1]In traditional "3+3" clinical phase I trial designs, initially used to study cytotoxic drugs, dose-limiting toxicity (DLT) was used instead of pharmacological markers to guide dose increment.
-
【2022 Breast Tumor Elite Practice and Exchange Project】Session 13 Anhui Station September 9
Time of Update: 2022-09-30
Meeting information Live timeSeptember 9, 2022 13:30-17:45 Day of the meeting Scan the poster QR code to watch this live broadcast We will continue to pay attention to the follow-up sessions and synchronize the live broadcast, so stay tuned!
-
Detailed interpretation of CEA rise, beginners to see this!
Time of Update: 2022-09-30
1. Before treatment, the tumor status, survival period and whether there are indications for surgery: the lower the CEA concentration, the earlier the stage, the smaller the possibility of tumor metastasis and recurrence, and the longer the survival time; Conversely, the higher the concentration, the later the stage, the greater the difficulty of excision, and the worse the prognosis;2.
-
Blood: efficacy and safety of Cilta-cel in patients with progressive multiple myeloma
Time of Update: 2022-09-30
CARTITUDE-2 is a Phase 2 multi-cohort study evaluating the efficacy and safety of Cilta-cel, an anti-BCMA chimeric antigen receptor T cell therapy, in a variety of myeloma patient populations.
-
Cell Death and Disease: Simultaneous expression of SMYD3 and PKM2 can serve as a new biomarker for diffuse large B-cell lymphoma
Time of Update: 2022-09-30
SMYD3 promotes aerobic glycolysis in diffuse large B-cell lymphoma via H3K4me3-mediated PKM2 transcription.
SMYD3 promotes aerobic glycolysis in diffuse large B-cell lymphoma via H3K4me3-mediated PKM2 transcription.
SMYD3 promotes aerobic glycolysis in diffuse large B-cell lymphoma via H3K4me3-mediated PKM2 transcription.
-
Nature Sub-Journal: Why Exercise Prevents Cancer? Exercise metabolism of lactic acid, can enhance anti-cancer immunity
Time of Update: 2022-09-30
The study shows that lactic acid can increase the number of tumor-infiltrating CD8+ T cells and enhance anti-tumor immunity, and this finding is expected to be used to develop new strategies to enhance the anti-tumor effect of cancer immunotherapy.
-
【CLEAR Currier a daily case】Lower abdominal mass, how do you diagnose it?
Time of Update: 2022-09-30
Often bilateral ovarian metastasis, high malignancy, very poor prognosis, easy to occur in 40 to 50 years old, often metastatic symptoms are more obvious, showing lower abdominal mass, rapid growth, and abdominal distention, pain.
-
When metabolism meets epigenetics, how to get to the top of the journal? Nature sub-journal tells you the secret!
Time of Update: 2022-09-30
Spotlight: metabolic problems (hypoxia); Tumor microenvironment Oncology research is becoming more and more inward-looking, and it is even more difficult to publish high-scoring articles in the field of oncology.
-
Eur Urol: Efficacy and safety assessment of Darolutamide in patients with non-metastatic prostate cancer
Time of Update: 2022-09-30
Recently, researchers from Germany published an article in Eur Urol evaluating the efficacy and safety of darolutamide and placebo in patients stratified at PSADT>6 or ≤6 months.
-
Science Advances: Bao Zhenan's team develops wearable devices to monitor tumor changes in the body in real time and accelerate the development of anti-cancer drugs
Time of Update: 2022-09-30
On September 16, 2022, Stanford University's Bao Zhenan team published a research paper titled "A flexible electronic strain sensor for the real-time monitoring of tumor regression" in the journal Science Advances.
-
The octogenarian woman was bitten by a dog, and the wound was simply treated to infect both bacteria
Time of Update: 2022-09-30
The isolated Pasteurella canis in this case is an animal pathogen and humans can become infected with cat or dog bites.
The isolated Pasteurella canis in this case is an animal pathogen and humans can become infected with cat or dog bites.
-
What are the imaging tests for stomach cancer?
Time of Update: 2022-09-30
Barium-barium double angiography is also very popular in China, but because it has not been taken seriously, and is greatly affected by the experience of the operator, its early gastric cancer diagnosis rate is low, and it has gradually been replaced by gastroscopy.
-
Lancet Sub-Journal (IF=17) Chinese Medical University Professor Wu Qijun Team: A systematic review of artificial intelligence in the field of ovarian cancer imaging diagnosis
Time of Update: 2022-09-30
Reference message: —END—content is [iNature]In recent years, the team of Professor Wu Qijun of Shengjing Hospital affiliated to China Medical University has carried out a series of studies on the etiology, diagnosis and prognostic factors of ovarian cancer patients.
-
Top Journals and National Nature's Preference: How Can Organoids Publish Top Journals of Oncology with 3 Pictures? Smooth application country natural?
Time of Update: 2022-09-30
flow chart Third, the content of the study Figure 1-2: Construct organoids and characterize and identify their features To determine whether the constructed organoids can represent molecular subtypes of different pancreatic cancers, the authors performed immunohistochemical identification of 4 biopsy tissues and 6 organoids, transcriptomics detected in 9 organoids, and compared the molecular subtypes of RNA-seq data from PDOs using two algorithms (Figure2A).
-
JMC: Novel STAT3 inhibitor HP590, which is effective for stomach cancer orally
Time of Update: 2022-09-30
On September 14, 2022, the Journal of Medicinal Chemistry, an authoritative journal of international medicinal chemistry, published online, "Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual
